

## A synopsis of eukaryotic N<sup>α</sup>-terminal acetyltransferases: nomenclature, subunits and substrates

Bogdan Polevoda<sup>1</sup>, Thomas Arnesen<sup>2,3,4</sup> and Fred Sherman\*<sup>1</sup>

Address: <sup>1</sup>Department of Biochemistry and Biophysics, University of Rochester Medical Center, Rochester, NY 14642, USA, <sup>2</sup>Department of Molecular Biology, University of Bergen, N-5020 Bergen, Norway, <sup>3</sup>Department of Surgical Sciences, University of Bergen, N-5020 Bergen, Norway and <sup>4</sup>Department of Surgery, Haukeland University Hospital, N-5021 Bergen, Norway

Email: Bogdan Polevoda - Bogdan\_Polevoda@urmc.rochester.edu; Thomas Arnesen - Thomas.Arnese@mbi.uib.no; Fred Sherman\* - Fred\_Sherman@urmc.rochester.edu

\* Corresponding author

from NAT 2007 and 2008 Symposia: Protein N-terminal Acetylation and Protein N-terminal Acetyltransferases (NATs) Bergen, Norway, . 24–25 May 2007 and 11–13 September 2008

Published: 4 August 2009

BMC Proceedings 2009, 3(Suppl 6):S2 doi:10.1186/1753-6561-3-S6-S2

This article is available from: <http://www.biomedcentral.com/1753-6561/3/S6/S2>

© 2009 Polevoda et al; licensee BioMed Central Ltd.


This is an open access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

### Abstract

We have introduced a consistent nomenclature for the various subunits of the NatA-NatE N-terminal acetyltransferases from yeast, humans and other eukaryotes.

### Introduction

N-terminal acetylation has been extensively studied in yeast and humans and represents one of the most common protein modifications in eukaryotes, occurring on approximately 57% of yeast proteins and 84% human proteins [1], although it is rare in prokaryotes. Eukaryotic proteins initiate with methionine residues, which are cleaved from nascent chains if the penultimate residue has a radius of gyration of 1.29 Å or less [2]. N-terminal acetylation subsequently occurs on certain of the proteins, either containing or lacking the methionine residue, as depicted in Fig. 1. The salient features of N-terminal acetylation are summarized in Table 1 and Fig. 2. Detailed reviews on the N-terminal acetyltransferases have appeared [3-7], and the N-terminal acetylation status of 742 human and 616 yeast protein N-termini have been compiled [1]. The wide range and diversity of substrates is due in part to the large number of different N-terminal acetylating enzymes, NatA-NatE. The sequence requirements for N-terminal acetylation vary with the N-terminal




**Figure 1**

**A summary of the major pathways of N-terminal processing in eukaryotes, showing the four different termini.** 1: Uncleaved and unacetylated Met-Xxx- N-termini; 2: Cleaved and unacetylated Xxx-N-termini; 3: Uncleaved and NatB/NatC acetylated Ac-Met-Xxx- N-termini; 4: Cleaved and NatA acetylated Ac-Xxx-N-termini. See Table 1 and Figure 2 for more detail.

**Table 1: Revised nomenclature for N-terminal acetyltransferases**

Type	NatA	NatB	NatC	NatD	NatE
Original					
Catalytic subunit	Ard1p	Nat3p	Mak3p	Nat4p	Nat5p
Auxiliary subunit	Nat1p	Mdm20p	Mak10p Mak31p		†
Revised					
Catalytic subunit	Naa10p	Naa20p	Naa30p	Naa40p	Naa50p
Auxiliary subunit	Naa15p	Naa25p	Naa35p Naa38p		†
Number of yeast substrates	~2,000	~1,000	~250	2?	?
Substrates*	Ser- Ala- Gly- Thr- Val-‡ Cys-¶	Met-Glu- Met-Asp- Met-Asn-	Met-Ile- Met-Leu- Met-Trp- Met-Phe-	Ser-Gly-etc-	?
		-----2 to 8 amino acids-----		30-50 a. a	?

Naa50p is inferred to be an N-terminal acetyltransferase because of its sequence homology to known NATs.  
 \* Acetylation occurs at least partially on all proteins with Met-Glu-, Met-Asp- and Met-Asn- termini, but only on subclasses of proteins with the other termini.  
 † Naa15p may be an auxiliary subunit of NatE, as well as an auxiliary subunit of NatA.  
 ‡ Found in humans but not yeast (see Figure 2 legend).  
 ¶ One example found in yeast (see Figure 2 legend).



**Figure 2**  
**The major pathways of N-terminal processing in eukaryotes.** Two methionine aminopeptidases (MAP), Map1p and Map2p, cleave N-terminal methionine residues that have small side chains (glycine, alanine, serine, cysteine, threonine, proline, and valine), although methionine is retained on some proteins having penultimate residues of valine. Subsequently, NatA, NatB, and NatC acetylate specific sequences as shown in the figure and in Table 1. Acetylation occurs at least partially on all proteins with Met-Glu-, Met-Asp- and Met-Asn- termini, but only on subclasses of proteins with the other termini. For example, acetylation occurs at least partially on 43% of proteins in yeast and on 96% of proteins in humans with Ala- termini. In addition, Ac-Cys-, Ac-Val-, Ac-Met-Met-, and Ac-Met-Lys- termini occurs on some proteins from humans but not from yeast; it is unknown which NATs are responsible for Ac-Cys-, Ac-Met-Met-, and Ac-Met-Lys- acetylations.

acetyltransferase. Only two amino acid residues, Met-Asn-, Met-Asp-, or Met-Glu-, are required for at least partial N-terminal acetylation by NatB [1,8]. On the other hand, 30 to 50 specific amino acids are required for N-terminal acetylation by NatD [9]. Each of the three major N-terminal acetyltransferases, NatA, NatB and NatC, contain a catalytic subunit, and one or two auxiliary subunits (Table 1). The sequence and functions of the yeast and human orthologous subunits are obviously related. A yeast *ard1-Δ nat1-Δ* strain was phenotypically complemented by *hARD1 hNAT1*, suggesting that yNatA and hNatA are similar. However, heterologous combinations, *hARD1 yNAT1* and *yARD1 hNAT1*, were not functional in yeast, suggesting significant structural subunit differences between the species [1].

**Nomenclature**

During a recent international meeting on N-terminal acetylation, it was pointed out that there is critical need to revise the gene symbols encoding the N-terminal acetyltransferases. The main reason for changing the nomenclature is so that each of the orthologous genes from different species would have the same name. Furthermore, orthologous genes were assigned not only by similarity of their sequences, but also by their action on the same set of proteins. Yeast NatA and human NatA were shown to acetylate the same set proteins by comparing a normal yeast strain with the mutant *naa10-Δ naa15-Δ hNAA10 hNAA15* [1].

**Table 2: Paralogs**

Subunit	Complex
Catalytic subunit Naa10p, Naa11p	NatA(10+15); NatA(10+16); NatA(11+15); NatA(11+16)
Auxiliary subunit Naa15p, Naa16p	

Almost all human NAT subunit genes encode alternative splicing isoforms whose functions are in question, and are not considered here.

**Table 3: Synonyms**

Primary name	Synonyms	Accession no.		
		Yeast	Human	References
Naa10p	Ard1p; TE2	P07347	P41227	[12-14]
Naa11p	Ard2p	-	Q9BSU3	[15]
Naa15p	Nat1p; NARG1; NATH; TBDN	P12945	Q9BXJ9	[16-20]
Naa16p	Nat2p; NARG1L	-	Q6N069	[20,21]
Naa20p	Nat3p; hNat5p	Q06504	P61599	[8,22,23]
Naa25p	Mdm20p; p120	Q12387	Q14CX7	[8,23]
Naa30p	Mak3p; hNat12p	Q03503	Q147X3	[24-26]
Naa35p	Mak10p; hEGAP	Q02197	Q5VZE5	[24,25,27]
Naa38p	Mak31p; hLsm8p	P23059	O95777	[24,25,27]
Naa40p	Nat4p; hNat11p	Q04751	Q86UY6	[28]
Naa50p	Nat5p; hNat13p; San	Q08689	Q9GZZ1	[29-31]

An example of standard symbols: Protein, Naa10p; Gene, *NAA10*; Deleted gene, *naa10-Δ*. hNaa10p, human; yNaa10p, yeast (*S. cerevisiae*); mNaa10p, mouse.

The use of the different symbols *NAT*, *ARD*, *MDM*, and *MAK* is confusing, and does not provide useful information, especially when applied to human NATs. We believe it can be misleading to assign a gene symbol based on one phenotype of a mutant when a large number of proteins are affected, and when the mutant is pleiotropic.

Most importantly, different orthologous genes should have different names. The symbols *NAT1*, *NAT2* and *NAT3* denote human genes encoding arylamine N-acetyltransferases, which are distinct from N-terminal acetyltransferases [10]. On the other hand, NCBI has designated the human homologue of the yeast *NAT* genes as follows: y*NAT1* designated as h*NARG1*; y*NAT3* designated as h*NAT5*; and y*NAT5* designated as h*NAT13*. Also, *ARD1* is used to describe the ADP-ribosylation factor domain protein 1 [11].

Therefore, in this paper we have introduced a new nomenclature for protein N-terminal acetyltransferases in eukaryotes (Table 1). It is important to note that *NAA* (No acetyltransferases) is not used to designate any other gene in yeast or higher eukaryotes. We have assigned each of the subunits of the NatA-NatE complexes a Naa symbol, as presented in Table 1. We have also recommended a nomenclature for paralogs of human NatA complexes

containing either Naa10p or Naa11p in combination with either Naa15p or Naa16p (Table 2). The revised symbols, along with synonyms from yeast and humans, are presented in Table 3. Clearly, this revised nomenclature will greatly diminish the confusion in describing orthologous subunits from different species.

### Competing interests

The authors declare that they have no competing interests.

### Authors' contributions

All authors wrote the manuscript and approved the final version.

### Acknowledgements

This work was supported by the Norwegian Health region West (to T.A.), the Norwegian Research Council (to T.A), and the National Institutes of Health Grant R01 GM12702 (to F.S.).

This article has been published as part of *BMC Proceedings* Volume 3 Supplement 6, 2009: Proceedings of the 2007 and 2008 Symposia on Protein N-terminal Acetylation. The full contents of the supplement are available online at <http://www.biomedcentral.com/1753-6561/3?issue=S6>

### References

- Arnesen T, Van Damme P, Polevoda B, Helsen K, Evjenth R, Colaert N, et al.: **Proteomics analyses reveal the evolutionary conser-**

- vation and divergence of N-terminal acetyltransferases from yeast and humans. *Proc Natl Acad Sci USA* 2009, **106**:8157-8162.
2. Sherman F, Stewart JW, Tsunasawa S: **Methionine or not methionine at the beginning of a protein.** *Bioessays* 1985, **3**:27-31.
  3. Arnesen T, Thompson PR, Varhaug JE, Lillehaug JR: **The Protein Acetyltransferase ARD1: A Novel Cancer Drug Target?** *Curr Cancer Drug Targets* 2008, **8**:545-553.
  4. Gromyko D, Starheim KK, Velde R, Varhaug JE, Arnesen T: **Human N-terminal acetyltransferases: Identification and biological significance.** *BMC Proc* 2009, **3**(Suppl 3):S3.
  5. Polevoda B, Norbeck J, Takakura H, Blomberg A, Sherman F: **Identification and specificities of N-terminal acetyltransferases from *Saccharomyces cerevisiae*.** *EMBO J* 1999, **18**:6155-6168.
  6. Polevoda B, Sherman F: **N-terminal acetyltransferases and sequence requirements for N-terminal acetylation of eukaryotic proteins.** *J Mol Biol* 2003, **325**:595-622.
  7. Polevoda B, Sherman F: **Composition and function of the eukaryotic N-terminal acetyltransferase subunits.** *Biochemical and Biophysical Research Communications* 2003, **308**:1-11.
  8. Polevoda B, Cardillo TS, Doyle TC, Bedi GS, Sherman F: **Nat3p and Mdm20p are required for function of yeast NatB Nalpha-terminal acetyltransferase and of actin and tropomyosin.** *J Biol Chem* 2003, **278**:30686-30697.
  9. Polevoda B, Hoskins J, Sherman F: **Properties of Nat4, an N(alpha)-Acetyltransferase of *Saccharomyces cerevisiae* that Modifies N termini of Histones H2A and H4.** *Mol Cell Biol* 2009.
  10. Vagena E, Fakis G, Boukouvala S: **Arylamine N-acetyltransferases in prokaryotic and eukaryotic genomes: a survey of public databases.** *Curr Drug Metab* 2008, **9**:628-660.
  11. Vichi A, Payne DM, Pacheco-Rodriguez G, Moss J, Vaughan M: **E3 ubiquitin ligase activity of the trifunctional ARD1 (ADP-ribosylation factor domain protein 1).** *Proc Natl Acad Sci USA* 2005, **102**:1945-1950.
  12. Arnesen T, Anderson D, Baldersheim C, Lanotte M, Varhaug JE, Lillehaug JR: **Identification and characterization of the human ARD1-NATH protein acetyltransferase complex.** *Biochem J* 2005, **386**:433-443.
  13. Tribioli C, Mancini M, Plassart E, Bione S, Rivella S, Sala C, et al.: **Isolation of new genes in distal Xq28: transcriptional map and identification of a human homologue of the ARD1 N-acetyltransferase of *Saccharomyces cerevisiae*.** *Hum Mol Genet* 1994, **3**:1061-1067.
  14. Whiteway M, Szostak JW: **The ARD1 gene of yeast functions in the switch between the mitotic cell cycle and alternative developmental pathways.** *Cell* 1985, **43**:483-492.
  15. Arnesen T, Betts MJ, Pendino F, Liberles DA, Anderson D, Caro J, et al.: **Characterization of hARD2, a processed hARD1 gene duplicate, encoding a human protein N-alpha-acetyltransferase.** *BMC Biochem* 2006, **7**:13.
  16. Fluge O, Bruland O, Aksten LA, Varhaug JE, Lillehaug JR: **NATH, a novel gene overexpressed in papillary thyroid carcinomas.** *Oncogene* 2002, **21**:5056-5068.
  17. Gendron RL, Adams LC, Paradis H: **Tubedown-1, a novel acetyltransferase associated with blood vessel development.** *Dev Dyn* 2000, **218**:300-315.
  18. Mullen JR, Kayne PS, Moerschell RP, Tsunasawa S, Gribskov M, Colavito-Shepanski M, et al.: **Identification and characterization of genes and mutants for an N-terminal acetyltransferase from yeast.** *EMBO J* 1989, **8**:2067-2075.
  19. Park EC, Szostak JW: **ARD1 and NAT1 proteins form a complex that has N-terminal acetyltransferase activity.** *EMBO J* 1992, **11**:2087-2093.
  20. Sugiura N, Adams SM, Corriveau RA: **An evolutionarily conserved N-terminal acetyltransferase complex associated with neuronal development.** *J Biol Chem* 2003, **278**:40113-40120.
  21. Arnesen T, Gromyko D, Kagabo D, Betts MJ, Starheim KK, Varhaug JE, et al.: **A novel human NatA N-alpha-terminal acetyltransferase complex: hNaa16p-hNaa10p (hNat2-hArd1).** *BMC Biochem* 2009, **10**:15.
  22. Ametzazurra A, Larrea E, Civeira MP, Prieto J, Aldabe R: **Implication of human N-alpha-acetyltransferase 5 in cellular proliferation and carcinogenesis.** *Oncogene* 2008, **27**:7296-7306.
  23. Starheim KK, Arnesen T, Gromyko D, Rynningen A, Varhaug JE, Lillehaug JR: **Identification of the human N(alpha)-acetyltransferase complex B (hNatB): a complex important for cell-cycle progression.** *Biochem J* 2008, **415**:325-331.
  24. Polevoda B, Sherman F: **NatC Nalpha-terminal acetyltransferase of yeast contains three subunits, Mak3p, Mak10p, and Mak31p.** *J Biol Chem* 2001, **276**:20154-20159.
  25. Starheim KK, Gromyko D, Evjenth R, Rynningen A, Varhaug JE, Lillehaug JR, et al.: **Knockdown of the Human N(alpha)-Terminal Acetyltransferase Complex C (hNatC) Leads to p53-Dependent Apoptosis and Aberrant hArl8b Localization.** *Mol Cell Biol* 2009, **29**:3569-3581.
  26. Tercero JC, Wickner RB: **MAK3 encodes an N-acetyltransferase whose modification of the L-A gag NH2 terminus is necessary for virus particle assembly.** *J Biol Chem* 1992, **267**:20277-20281.
  27. Wenzlau JM, Garl PJ, Simpson P, Stenmark KR, West J, Artinger KB, et al.: **Embryonic growth-associated protein is one subunit of a novel N-terminal acetyltransferase complex essential for embryonic vascular development.** *Circ Res* 2006, **98**:846-855.
  28. Song OK, Wang X, Waterborg JH, Sternglanz R: **An Nalpha-acetyltransferase responsible for acetylation of the N-terminal residues of histones H4 and H2A.** *J Biol Chem* 2003, **278**:38109-38112.
  29. Arnesen T, Anderson D, Torsvik J, Halseth HB, Varhaug JE, Lillehaug JR: **Cloning and characterization of hNAT5/hSAN: an evolutionarily conserved component of the NatA protein N-alpha-acetyltransferase complex.** *Gene* 2006, **371**:291-295.
  30. Gautschi M, Just S, Mun A, Ross S, Rucknagel P, Dubaquié Y, et al.: **The yeast N(alpha)-acetyltransferase NatA is quantitatively anchored to the ribosome and interacts with nascent polypeptides.** *Mol Cell Biol* 2003, **23**:7403-7414.
  31. Williams BC, Garrett-Engele CM, Li Z, Williams EV, Rosenman ED, Goldberg ML: **Two putative acetyltransferases, san and deco, are required for establishing sister chromatid cohesion in *Drosophila*.** *Curr Biol* 2003, **13**:2025-2036.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:  
[http://www.biomedcentral.com/info/publishing\\_adv.asp](http://www.biomedcentral.com/info/publishing_adv.asp)

